By InvitationNot Applicable

Clinical Outcomes of Patients with LAL+ in At Least One Eye

United States25 participantsStarted 2024-10-16

Plain-language summary

The objective of this study is to collect data on bilateral pseudophakic patients implanted with the RxSight Light Adjustable Lens+ (LAL+) in at least one eye

Who can participate

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Adults with bilateral pseudophakia who have been implanted with the LAL+ in at least one eye and who have completed LDD light treatments * Sign a written Informed Consent Form Exclusion Criteria: * Visually significant eye disease

What they're measuring

Patient Satisfaction

Timeframe: 3-18 months after phacoemulsification

Trial details

NCT IDNCT06650358

SponsorFrank A. Bucci, Jr., M.D.

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2025-01-01

View on ClinicalTrials.gov More IOL, Cataract trials